Related Experiment Videos
[Experiences to date with oral gold therapy]
Wiener Klinische Wochenschrift. Supplementum
|January 1, 1984
Summary
Auranofin, an oral gold therapy, is effective for rheumatoid arthritis and juvenile chronic polyarthritis with low toxicity. It is not recommended for ankylosing spondylitis or late-stage disease.
Area of Science:
- Rheumatology
- Pharmacology
Context:
- Auranofin represents a significant advancement in gold-based therapies for inflammatory arthropathies.
- Recent clinical trials have expanded its application beyond rheumatoid arthritis to juvenile chronic polyarthritis.
Purpose:
- To evaluate the efficacy and safety of auranofin in treating specific arthritic conditions.
- To define the appropriate indications and contraindications for auranofin therapy.
Summary:
- Auranofin is an oral gold compound demonstrating efficacy with manageable toxicity.
- Current evidence supports its use in rheumatoid arthritis and juvenile chronic polyarthritis, particularly when other treatments fail or are contraindicated.
- It is not indicated for ankylosing spondylitis, other seronegative arthropathies, or in patients with late-stage disease.
Impact:
- Provides a valuable oral treatment option for specific inflammatory arthritis patients.
- Guides clinical decision-making regarding auranofin's place in therapy.
- Highlights the importance of patient selection for optimal treatment outcomes.